Loading cancer entity…
Loading cancer entity…
Clinical trials
4,036 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (701)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00030394 | Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00002798 | Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | completed | Phase 3 | 880 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00003528 | Raltitrexed in Treating Children With Refractory Acute Leukemia | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00053963 | FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00093418 | S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia | completed | Phase 2 | 296 | National Cancer Institute (NCI)NIH | 1 | Jan 15, 2013 | clinicaltrials |
| NCT00101088 | Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | terminated | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2013 | clinicaltrials |
| NCT00098826 | SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 11, 2013 | clinicaltrials |
| NCT00947830 | Investigating Intracellular and Plasma Imatinib Levels in Chronic Myeloid Leukemia(OCT-1) | completed | — | 81 | Brian LeberOTHER | 1 | Jan 11, 2013 | clinicaltrials |
| NCT01766375 | the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient(IDBUCY) | unknown | Phase 3 | 200 | Guangxi Medical UniversityOTHER | 1 | Jan 11, 2013 | clinicaltrials |
| NCT00012376 | Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00112853 | Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 1 | 100 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00131989 | Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | completed | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00004918 | Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00357708 | Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00125606 | Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide | terminated | Phase 3 | 30 | University Hospital MuensterOTHER | 1 | Dec 18, 2012 | clinicaltrials |
| NCT00186342 | Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies | completed | N/A | 120 | Stanford UniversityOTHER | 1 | Dec 17, 2012 | clinicaltrials |
| NCT00915252 | Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)(AML-AZA) | completed | Phase 2 | 214 | University Hospital MuensterOTHER | 1 | Dec 17, 2012 | clinicaltrials |
| NCT00005641 | Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation | terminated | Phase 2 | — | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 11, 2012 | clinicaltrials |
| NCT00005852 | Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant | terminated | Phase 2 | — | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Dec 11, 2012 | clinicaltrials |
| NCT00790855 | Bendamustine in Acute Leukemia and MDS | terminated | Phase 1 / Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 4, 2012 | clinicaltrials |
| NCT01716364 | Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome | unknown | Phase 1 | 6 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Dec 4, 2012 | clinicaltrials |
| NCT00513175 | Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia | completed | — | 44 | University of California, San FranciscoOTHER | 1 | Nov 9, 2012 | clinicaltrials |
| NCT00900406 | Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant | completed | — | 190 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Nov 6, 2012 | clinicaltrials |
| NCT01270984 | Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects(Imatinib) | completed | Phase 1 | 30 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Oct 31, 2012 | clinicaltrials |
| NCT00266136 | Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG) | completed | Phase 3 | 3,500 | University Hospital MuensterOTHER | 1 | Oct 26, 2012 | clinicaltrials |
| NCT00005622 | Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders | completed | Phase 2 | 72 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 25, 2012 | clinicaltrials |
| NCT00069992 | Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML(MPDMDSBMT) | terminated | Phase 2 | 7 | Baylor College of MedicineOTHER | 1 | Oct 10, 2012 | clinicaltrials |
| NCT00861874 | A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 13 | University of RochesterOTHER | 1 | Oct 10, 2012 | clinicaltrials |
| NCT00296023 | Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer | completed | N/A | 25 | University of California, San FranciscoOTHER | 1 | Oct 4, 2012 | clinicaltrials |
| NCT00301912 | Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | withdrawn | Phase 2 | 0 | University of California, San FranciscoOTHER | 1 | Oct 2, 2012 | clinicaltrials |
| NCT00787761 | Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer | completed | Phase 2 | 24 | Northside Hospital, Inc.OTHER | 1 | Oct 1, 2012 | clinicaltrials |
| NCT00062231 | Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer | terminated | N/A | 351 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Sep 24, 2012 | clinicaltrials |
| NCT01615757 | Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation(Ara-c) | unknown | Phase 3 | 180 | All India Institute of Medical SciencesOTHER | 1 | Sep 17, 2012 | clinicaltrials |
| NCT00666211 | Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain | completed | Phase 3 | 98 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 6, 2012 | clinicaltrials |
| NCT00710528 | Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 192 | Gilead SciencesINDUSTRY | 1 | Aug 31, 2012 | clinicaltrials |
| NCT01037556 | PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia | unknown | Phase 1 / Phase 2 | 50 | Proacta, IncorporatedINDUSTRY | 1 | Aug 31, 2012 | clinicaltrials |
| NCT00219726 | Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation | completed | Phase 2 | 30 | Poitiers University HospitalOTHER | 1 | Aug 29, 2012 | clinicaltrials |
| NCT00030186 | Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation | completed | Phase 2 | 37 | CephalonINDUSTRY | 0 | Aug 23, 2012 | clinicaltrials |
| NCT00038818 | CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation | terminated | N/A | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 23, 2012 | clinicaltrials |
| NCT00146055 | Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood | completed | Phase 2 | 60 | University of Michigan Rogel Cancer CenterOTHER | 1 | Aug 9, 2012 | clinicaltrials |
| NCT00762632 | Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 40 | Technical University of MunichOTHER | 1 | Aug 8, 2012 | clinicaltrials |
| NCT00088218 | Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS). | completed | Phase 2 | 95 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00267085 | Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease | completed | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00382590 | Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients | completed | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00418951 | Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections | completed | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00480987 | Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) | terminated | Phase 1 / Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00569660 | Ph II Study of Azacitidine in Myelofibrosis | completed | Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT01031498 | Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting | completed | Phase 2 | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00443300 | Effectiveness of Protected Environment Rooms for AML and MDS | terminated | — | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Jan 17, 2013source: clinicaltrials